SGLT2 inhibitors exert the same effect in patients with type 1 diabetes mellitus (T1DM), although T1DM is not an indication for SGLT2 inhibitor therapy (Garg et al., 2017). The gene discussed is SLC5A2; the disease is diabetes mellitus.